Nate N. Waldron

Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression

Amy P.N. Skubitz, Elizabeth Taras, Kristin L.M. Boylan et al. · Gynecologic Oncology · 2013 · 106 citations · Full text

Oncology, Medicine, Gynecology +8

Targeting Tumor-Initiating Cancer Cells with dCD133KDEL Shows Impressive Tumor Reductions in a Xenotransplant Model of Human Head and Neck Cancer

Nate N. Waldron, Dan S. Kaufman, Seunguk Oh et al. · Molecular Cancer Therapeutics · 2011 · 76 citations · Full text

Xenotransplant Model, Immunology, Immunotherapy +18

CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy

Christopher L. Moertel, Junzhe Xia, Rebecca S. LaRue et al. · Journal for ImmunoTherapy of Cancer · 2014 · 74 citations · Full text

A bispecific EpCAM/CD133-targeted toxin is effective against carcinoma

Nate N. Waldron, Sanford H. Barsky, Phillip R. Dougherty et al. · Targeted Oncology · 2013 · 41 citations

Tumor Biology, Immunology, Immune Checkpoint Inhibitor +5

Immunotoxin targeting CD133+ breast carcinoma cells

John R. Ohlfest, David M. Zellmer, Jayanth Panyam et al. · Drug Delivery and Translational Research · 2012 · 39 citations

Breast Oncology, Immunology, Breast Cancer +3